Galecto
Boston, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Galecto is a clinical-stage biotechnology company developing novel small-molecule therapeutics that target the core biological drivers of fibrosis, inflammation, and cancer. Founded by leading scientists and biotech executives with more than a decade of research into galectin biology and LOXL2 modulation, the company has built deep expertise in pathways central to complex and often devastating dis
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 18
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (DMRA)
- Website
- galecto.com
- Company page
Recent activity at Galecto
- : Galecto Appoints Sherwin Sattarzadeh as Chief Operating Officer and Dr. Becker Hewes as Chief Medical Officer
- : Galecto
- : Galecto, Inc. Acquires Damora Therapeutics, Inc.
- : SEC 8-K (1.01): On November 10, 2025, Galecto, Inc. executed an Agreement and Plan of Merger to acquire Damora Therapeutics, Inc. This merger was executed with the involvement of two wholly owned subsidiaries of Galecto, namely Daylight Merger Sub I, Inc. and Daylight Merger Sub II, LLC. The terms of the Merger Agreement stipulate that Damora will be a wholly owned subsidiary of Galecto post-merger. This strategic acquisition aims to enhance Galecto's operational portfolio and expand its market reach in the biotech sector.
- : Galecto, Inc.
- : Galecto Inc.
Galecto funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Venture | $285.0M |
| Nov 2020 | Venture | $64.2M |
| Jan 2020 | Venture | $79.1M |
Leadership
- Hans Schambye, Executive Officer, Director
- Karen Wagner, Director
- Chao Khuong, Director
- Erez Chimovits, Director
- Chandra Leo, Director
- Soren Moller, Director
- Soren Lemonius, Director
- Carl Goldfischer, Director
- Stephan Christgau, Director
- David Shapiro, Director
- Amit Munshi, Director
- Jennifer Jarrett, Chief Executive Officer
Verified email and direct lines for Galecto’s decision-makers are on Fundz. See plans
Employee benefit plans
Galecto files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Galecto in the news
- Galecto Announces Acquisition of Damora Therapeutics - Yahoo Finance (Nov 10, 2025)
- Galecto (NASDAQ: GLTO) outlines Damora acquisition, $285M PIPE and Cayman redomestication - Stock Titan (Dec 16, 2025)
- US: Galecto acquires Damora Tx and raises US$285m from Series C - Investors in Healthcare (Nov 12, 2025)
- Assessing Galecto (GLTO) Valuation After Sharp Short-Term Share Price Momentum - Yahoo Finance (Feb 15, 2026)
- Galecto cans lung fibrosis work after phase 2 fail, with all eyes now on liver cirrhosis med - Fierce Biotech (Aug 15, 2023)
- Galecto Drops Idiopathic Pulmonary Fibrosis Hopeful After Phase II Flop - BioSpace (Aug 15, 2023)
- Novo Seeds Portfolio Company Galecto Biotech Raises €79 Mill - novoholdings.dk (Oct 26, 2018)
- Galecto Biotech - Nature (Jun 10, 2013)
Companies similar to Galecto
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Inhibitor Therapeutics · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Elevation Oncology · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Savara Inc · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
- Immuneering · Biotechnology, Healthcare, Health Care, Medical, Therapeutics
About Galecto: questions and answers
What does Galecto do?
Galecto is a clinical-stage biotechnology company developing novel small-molecule therapeutics that target the core biological drivers of fibrosis, inflammation, and cancer. Founded by leading scientists and biotech executives with more than a decade of research into galectin biology and LOXL2 modulation, the company has built deep expertise in pathways central to complex and often devastating dis
Where is Galecto headquartered?
Galecto is headquartered in Boston, Massachusetts, United States.
How many employees does Galecto have?
Galecto has about 18 employees.
Has Galecto raised funding?
Yes. Fundz has recorded 3 funding events for Galecto. The most recent, $285.0M, was in Nov 2025.
Who leads Galecto?
Jennifer Jarrett is a Chief Executive Officer at Galecto.
What is the latest news on Galecto?
On Jan 06, 2026, Galecto Appoints Sherwin Sattarzadeh as Chief Operating Officer and Dr. Becker Hewes as Chief Medical Officer
Is Galecto a public company?
Yes. Galecto is publicly traded under the ticker DMRA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy